Drug Profile
Research programme: blood disorder therapeutics - Bicycle Therapeutics/Bioverativ
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Developer Bicycle Therapeutics; Bioverativ
- Class Coagulants; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia; Sickle cell anaemia
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Haemophilia in United Kingdom
- 28 Oct 2021 No recent reports of development identified for research development in Sickle-cell-anaemia in United Kingdom
- 08 Mar 2018 Bioverativ has been acquired by Sanofi